Name: Meet Team Norway at ESRR 2026
Start: 2026-04-16T08:00:00Z
End: 2026-04-19T16:00:00Z
Location: Bergen

Two men in white lab coats working with radiopharmaceuticals

Event has ended

16 April 2026 - 19 April 2026

Location: Bergen, Norway

Conference

As the global radiopharmaceutical field continues to accelerate, Norway is emerging as a strong and reliable partner across the radiopharma value chain.

At ESRR 2026, Invest in Norway, in partnership with NorTrials, will be present representing Norway’s radiopharmaceutical sector.

Norway offers:

World-class research environments in radiochemistry and nuclear medicine
Advanced infrastructure for isotope production and radiopharmaceutical development
Strong public–private collaboration
Stable regulatory frameworks and predictable market access
Strategic access to European and global markets

From early-stage research and isotope production to CDMO capabilities, clinical translation and commercialisation support, Team Norway brings expertise across the full value chain.

Visit Booths 20 and 21 to learn more about how Norway is shaping the radiopharmaceutical landscape and to meet representatives from across the national ecosystem.

Contact us

Contact our experts to discuss scientific and clinical progress in radiopharmaceuticals.

Signe Øien Fretland

Head of NorTrials coordinating unit; Cand. Pharm.

Contact via email

Partners

NORTRIALS

Website

INVEST IN NORWAY

Website

Man in gray blazer and glasses greeting a woman in a black dress

Important conditions

Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.

Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.

Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.